FATE EBITDA Growth
Fate Therapeutics Inc · EBITDA Growth
FATE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported23.91%period ending
FATE TTM EBITDA YoY % (-40.88% → 23.91%)
Year-over-year change
High-resolution chart · PNG
FATE ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 23.9084% | |
| 23.3859% | |
| 23.8927% | |
| 14.3822% | |
| 3.9647% | |
| 10.4453% | |
| -13.6786% | |
| -2.7541% | |
| 19.6613% | |
| 22.1118% | |
| 46.7665% | |
| 45.2267% | |
| 20.2255% | |
| 2.3883% | |
| -29.1874% | |
| -62.9877% | |
| -50.3514% | |
| -64.9543% | |
| -65.9403% | |
| -45.1033% | |
| -41.884% | |
| -25.1073% | |
| -32.6886% | |
| -45.265% | |
| -57.392% | |
| -57.679% | |
| -47.8916% | |
| -36.7135% | |
| -34.1285% | |
| -55.4657% | |
| -56.4562% | |
| -65.7848% | |
| -57.6894% | |
| -34.9713% | |
| -31.3238% | |
| -19.9036% | |
| -21.5348% | |
| -19.4976% | |
| -14.4196% | |
| -15.5851% | |
| -9.1137% | |
| -11.2868% | |
| -11.0087% | |
| -12.1902% | |
| -15.2742% | |
| -13.217% | |
| -32.8471% | |
| -33.625% | |
| -40.8752% |